Search
for
Sort by
Research 601–630 of 1000+
- ANALYSIS OF ADVERSE DRUG REACTIONS (ADRs) AND THEIR SEVERITY IN BREAST CANCER PATIENTS TREATED WITH THE DOCETAXEL-DOXORUBICIN REGIMEN AT SULTAN AGUNG ISLAMIC HOSPITAL
- Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
- The IVIG treatment response in autoimmune polyendocrine syndromes type 2 with anti-GAD65 antibody-associated stiff person syndrome: a case report and literature review
- Factors Affecting the Response and Patient Satisfaction of Topical Immunotherapy in Alopecia Areata: A Nationwide Study
- Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report
- Androgenetic alopecia; drug safety and therapeutic strategies
- Generalized pustular psoriasis responsive to PUVA and oral cyclosporin therapy
- Association Between Gender and Drug Cost for Over-the-Counter Minoxidil
- Impact of Chemotherapeutic Drug on People living with Cancer
- Urticaria, Drug Hypersensitivity Rashes, Nodules and Tumors, and Atrophic Diseases
- The PDGF/PDGFR pathway as a drug target
- Surface Lipids as Multifunctional Mediators of Skin Responses to Environmental Stimuli
- Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
- Ablative Fractional Resurfacing in Topical Drug Delivery: An Update and Outlook
- Treatment of androgenic disorders with dexamethasone: Dose-response relationship for suppression of dehydroepiandrosterone sulfate
- Cystine-thiamin-containing hair-growth formulation modulates the response to UV radiation in an in vitro model for growth-limiting conditions of human keratinocytes
- Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
- Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata
- TREATMENT OF SEVERE ALOPECIA AREATA USING METHOTREXATE AS AN ADJUNCTIVE DRUG IN COMBINATION WITH INTRAVENOUS AND ORAL CORTICOSTEROID
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Microgel emulsion loaded with recombinant oil body as a new drug delivery carrier to promote wound repair
- A prospective observational study on drug safety monitoring and Pharmacoeconomics in patients with locally advanced unresectable NSCLC in a tertiary care hospital
- Preparing regenerative therapies for clinical application: proposals for responsible translation
- Modeling the pharmacodynamics of nandrolone doping drug and implications for anti‐doping testing
- Albendazole treatment of echinococcosis in humans: Effects on microsomal metabolism and drug tolerance
- Recent progress in PLGA-based microneedle-mediated transdermal drug and vaccine delivery
- Protective effect of Korean Red Ginseng against chemotherapeutic drug-induced premature catagen development assessed with human hair follicle organ culture model
- Experience with oral tofacitinib in severe alopecia areata with different clinical responses